DHEA derivative as insulin booster

Treatments for Type II diabetes typically take one of three therapeutic routes: increase insulin production, reduce glucose production or sensitize the effects of insulin. Hollis-Eden Pharmaceuticals Inc. believes that its HE3286 - a novel compound derived from the not-so-novel prohormone DHEA - could avoid the weight gain seen in approved insulin sensitizers.

Last week, the company presented data showing that HE3286 lowered glucose and increased insulin sensitivity in various animal models of Type II diabetes. HEPH expects to submit an IND for HE3286 this quarter(see B14). ...